RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyeGate Pharmaceuticals - Stock

EyeGate Pharmaceuticals Net Income 2024

EyeGate Pharmaceuticals Net Income

-8.87 M USD

Ticker

EYEG

ISIN

US30233M5031

WKN

A2PRBT

In 2024, EyeGate Pharmaceuticals's profit amounted to -8.87 M USD, a 33.36% increase from the -6.65 M USD profit recorded in the previous year.

The EyeGate Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2024e-
2023e-
2022e-
2021e-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-

EyeGate Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into EyeGate Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by EyeGate Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects EyeGate Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of EyeGate Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into EyeGate Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing EyeGate Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on EyeGate Pharmaceuticals’s growth potential.

EyeGate Pharmaceuticals Revenue, EBIT and net profit per share

DateEyeGate Pharmaceuticals RevenueEyeGate Pharmaceuticals EBITEyeGate Pharmaceuticals Net Income
2024e3.05 M undefined0 undefined-8.87 M undefined
2023e2.91 M undefined0 undefined-6.65 M undefined
2022e2.82 M undefined0 undefined-5.09 M undefined
2021e0 undefined0 undefined-7.47 M undefined
202010,000 undefined-8.21 M undefined-8.09 M undefined
20192.69 M undefined-7.11 M undefined-7.1 M undefined
20181.65 M undefined-10.84 M undefined-10.81 M undefined
2017410,000 undefined-14.56 M undefined-13.22 M undefined
2016670,000 undefined-13.35 M undefined-13.34 M undefined
20150 undefined-6.68 M undefined-8.39 M undefined
20140 undefined-2.46 M undefined-1.77 M undefined
20130 undefined-3.1 M undefined-3.88 M undefined
20120 undefined-5.85 M undefined-6.03 M undefined

EyeGate Pharmaceuticals stock margins

The EyeGate Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyeGate Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyeGate Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the EyeGate Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the EyeGate Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the EyeGate Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the EyeGate Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the EyeGate Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the EyeGate Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the EyeGate Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

EyeGate Pharmaceuticals Margin History

EyeGate Pharmaceuticals Gross marginEyeGate Pharmaceuticals Profit marginEyeGate Pharmaceuticals EBIT marginEyeGate Pharmaceuticals Profit margin
2024e0 %0 %-290.68 %
2023e0 %0 %-228.87 %
2022e0 %0 %-180.2 %
2021e0 %0 %0 %
20200 %-82,100 %-80,900.01 %
20190 %-264.31 %-263.94 %
20180 %-656.97 %-655.15 %
20170 %-3,551.22 %-3,224.39 %
20160 %-1,992.54 %-1,991.04 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

EyeGate Pharmaceuticals Aktienanalyse

What does EyeGate Pharmaceuticals do?

EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding EyeGate Pharmaceuticals's Profit Margins

The profit margins of EyeGate Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of EyeGate Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating EyeGate Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

EyeGate Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When EyeGate Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about EyeGate Pharmaceuticals Stock

How much profit has EyeGate Pharmaceuticals made this year?

EyeGate Pharmaceuticals has made -8.87 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 33.36% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does EyeGate Pharmaceuticals publish its earnings?

EyeGate Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of EyeGate Pharmaceuticals?

The profits of EyeGate Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of EyeGate Pharmaceuticals?

You can learn more about the earnings of EyeGate Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does EyeGate Pharmaceuticals pay?

Over the past 12 months, EyeGate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGate Pharmaceuticals is expected to pay a dividend of 0.09 USD.

What is the dividend yield of EyeGate Pharmaceuticals?

The current dividend yield of EyeGate Pharmaceuticals is .

When does EyeGate Pharmaceuticals pay dividends?

EyeGate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of April, May, June, July.

How secure is the dividend of EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals paid dividends every year for the past 2 years.

What is the dividend of EyeGate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.09 USD are expected. This corresponds to a dividend yield of 0.26 %.

In which sector is EyeGate Pharmaceuticals located?

EyeGate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyeGate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyeGate Pharmaceuticals from 6/6/2024 amounting to 0.154 USD, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did EyeGate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of EyeGate Pharmaceuticals in the year 2023?

In the year 2023, EyeGate Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyeGate Pharmaceuticals pay out the dividend?

The dividends of EyeGate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyeGate Pharmaceuticals

Our stock analysis for EyeGate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.